Principia Biopharma is a late-stage biopharmaceutical company focused on developing therapies for immune-related diseases. Co.'s proprietary Tailored Covalency® platform enables Co. to design and develop reversible covalent and irreversible covalent, small molecule inhibitors with potencies and selectivities. Co.'s clinical pipeline includes rilzabrutinib, PRN473 Topical, and PRN2246/SAR442168. Co.'s main candidate, rilzabrutinib, a wholly owned Bruton Tyrosine Kinase inhibitor, is in a Phase 3 trial for the treatment of pemphigus (pemphigus vulgaris and pemphigus foliaceus), and in a Phase 1/2 trial for the treatment of Immune Thrombocytopenia. We show 10 historical shares outstanding datapoints in our coverage of PRNB's shares outstanding history.
Understanding the changing numbers of PRNB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRNB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRNB by allowing them to research PRNB shares outstanding history
as well as any other stock in our coverage universe. |
Free PRNB Email Alerts:
Video: Shares Outstanding Importance
